Knight Therapeutics Company Profile (CVE:GUD)

About Knight Therapeutics (CVE:GUD)

Knight Therapeutics logoKnight Therapeutics Inc., a specialty pharmaceutical company, engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada and internationally. The company’s commercialized products include Impavido, an alkyllysophospholipid analogue drug for the treatment of visceral and cutaneous Leishmaniasis; Movantik for the treatment of opioid induced constipation; AzaSite to treat bacterial conjunctivitis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Flat Tummy Tea, a herbal detox tea; and FOCUSfactor, a dietary supplement. Its products under development comprise Probuphine to treat opioid addiction; NeurAxon family to treat acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; Iluvien to treat diabetic macular edema; and Netildex to treat ocular inflammation. The company’s products under development also include ATryn for the prevention of thromboembolic events; 60P family to treat tropical diseases; Advaxis family to treat HPV-associated cancers and other diseases; FLEXISEQ to treat pain and joint stiffness associated with osteoarthritis; Hand MD, a line of anti-aging hand skincare products; and Crescita family, a line of dermo-cosmetic products. In addition, it finances other life science companies; and invests in life sciences venture capital funds. The company is headquartered in Montreal, Canada.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: CVE:GUD
  • CUSIP: N/A
  • Web: www.gud-knight.com
Capitalization:
  • Market Cap: C$1.23 billion
  • Outstanding Shares: 142,765,000
Average Prices:
  • 50 Day Moving Avg: C$8.63
  • 200 Day Moving Avg: C$9.77
  • 52 Week Range: C$8.25 - C$11.03
P/E:
  • Trailing P/E Ratio: 60.07
  • P/E Growth: 2880.00
Sales & Book Value:
  • Annual Revenue: C$7.97 million
  • Price / Sales: 154.59
  • Book Value: C$6.87 per share
  • Price / Book: 1.26
Profitability:
  • EBIDTA: ($7,640,000.00)
Misc:
  • Average Volume: 169,151 shs.
  • Short Ratio: 4.2
 

Frequently Asked Questions for Knight Therapeutics (CVE:GUD)

What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "GUD."

Who are some of Knight Therapeutics' key competitors?

How do I buy Knight Therapeutics stock?

Shares of Knight Therapeutics and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Knight Therapeutics' stock price today?

One share of Knight Therapeutics stock can currently be purchased for approximately C$8.63.


MarketBeat Community Rating for Knight Therapeutics (CVE GUD)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  48 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  93
MarketBeat's community ratings are surveys of what our community members think about Knight Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Knight Therapeutics (CVE:GUD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Knight Therapeutics (CVE:GUD)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Knight Therapeutics (CVE:GUD)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Knight Therapeutics (CVE:GUD)
Current Year EPS Consensus Estimate: $0.10 EPS

Dividends

Dividend History for Knight Therapeutics (CVE:GUD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Knight Therapeutics (CVE:GUD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Knight Therapeutics (CVE:GUD)
Latest Headlines for Knight Therapeutics (CVE:GUD)
Source:
DateHeadline
finance.yahoo.com logoKnight Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : GUD-CA : June 23, 2017
finance.yahoo.com - June 23 at 3:38 PM
prnewswire.com logoBraeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE® in ... - PR Newswire (press release)
www.prnewswire.com - June 14 at 7:03 PM
finance.yahoo.com logoBraeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE(R) in Canada for Opioid Drug Dependence
finance.yahoo.com - June 13 at 11:10 AM
finance.yahoo.com logoBraeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE® in Canada for Opioid Drug Dependence
finance.yahoo.com - June 13 at 11:09 AM
fool.ca logoCan Knight Therapeutics Inc. Repeat the Success of Paladin Labs? - The Motley Fool Canada
www.fool.ca - May 19 at 10:06 AM
reuters.com logoBRIEF-Knight therapeutics Q1 EPS $0.04
www.reuters.com - May 12 at 11:15 PM
finance.yahoo.com logoEdited Transcript of GUD.TO earnings conference call or presentation 11-May-17 12:30pm GMT
finance.yahoo.com - May 11 at 11:10 PM
seekingalpha.com logoKnight Therapeutics' (KHTRF) Management on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 6:09 PM
finance.yahoo.com logoSynergy CHC Corp. Announces Private Placement Offering of up to US$20 Million
finance.yahoo.com - May 3 at 3:03 PM
finance.yahoo.com logoKnight to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference in Toronto
finance.yahoo.com - April 25 at 11:00 AM
finance.yahoo.com logoKnight Therapeutics Announces the Canadian commercialization of MOVANTIK®
finance.yahoo.com - March 13 at 11:10 AM
benzinga.com logoKnight Therapeutics Inc. Announces Board Change - Benzinga
www.benzinga.com - February 23 at 5:33 PM
streetinsider.com logoKnight Therapeutics Acquires 6.2M Shares of Protalix BioTherapeutics (PLX)
www.streetinsider.com - January 27 at 7:29 PM
finance.yahoo.com logoKnight Plants Small Seed Position In Protalix
finance.yahoo.com - January 27 at 12:04 AM
finance.yahoo.com logoKnight Disposes of Shares of Pediapharm Inc.
finance.yahoo.com - January 13 at 11:46 PM
finance.yahoo.com logoAPI Is Core to Knight's Successful Investment
finance.yahoo.com - January 9 at 4:27 PM
finance.yahoo.com logoMedicure Provides Apicore Secured Loan to Replace Knight Loan
finance.yahoo.com - January 9 at 4:27 PM
finance.yahoo.com logoThe Top 5 Buys of Canada's CI Can-Am Small Cap Fund
finance.yahoo.com - December 16 at 11:08 PM
reuters.com logoExclusive: Endo International considers sale of Paladin Labs to Knight Therapeutics: sources
www.reuters.com - November 4 at 4:17 PM
theglobeandmail.com logoIf $10,000 fell into your lap, what would you do?
www.theglobeandmail.com - September 1 at 8:16 AM
finance.yahoo.com logoKnight Medison Relationship Continues to Pay Dividends
finance.yahoo.com - August 15 at 10:16 AM
finanznachrichten.de logoSIFI S.p.A. and Knight Therapeutics Announce Canadian License Agreement for NETILDEX
www.finanznachrichten.de - August 2 at 5:37 PM
finanznachrichten.de logoKNIGHT THERAPEUTICS INC
www.finanznachrichten.de - May 26 at 12:31 PM
finance.yahoo.com logo3D Signatures Inc. and Plicit Capital Corp. Increase Minimum Financing and Receive Lead Order From and Enter Into Advisory Agreement With Knight Therapeutics Inc.
finance.yahoo.com - May 26 at 12:16 PM
finance.yahoo.com logoKnight Reports First Quarter 2016 Results
finance.yahoo.com - May 10 at 6:00 AM
finance.yahoo.com logoKnight Blooms at Healthcare Investor Conference in Toronto
finance.yahoo.com - April 25 at 8:00 AM
finance.yahoo.com logoKnight Receives NOD from Health Canada for ATryn(R)
finance.yahoo.com - April 25 at 8:00 AM
finance.yahoo.com logoKnight Finds EMPAthetic Partner for Neuragen(R) in the Middle East
finance.yahoo.com - April 25 at 8:00 AM
biz.yahoo.com logoQ4 2015 KNIGHT THERAPEUTICS Inc Earnings Release - Time Not Supplied
biz.yahoo.com - March 24 at 7:07 AM
finance.yahoo.com logoKnight Reports Fourth Quarter and Year-Ended December 31, 2015 Results
finance.yahoo.com - March 24 at 6:00 AM
finance.yahoo.com logoKnight Receives Dividend From Medison
finance.yahoo.com - March 23 at 8:00 AM
finance.yahoo.com logoKnight Partner Profounda Inc. Launches Impavido in U.S.
finance.yahoo.com - March 22 at 8:03 AM
finance.yahoo.com logoProfounda, Inc. launches Impavido® (miltefosine), the first and only oral Rx treatment for visceral, mucosal and cutaneous leishmaniasis, in the United States
finance.yahoo.com - March 22 at 7:59 AM
finance.yahoo.com logoKnight Obtains Impavido Worldwide Rights
finance.yahoo.com - March 15 at 8:00 AM
finance.yahoo.com logoKnight Therapeutics Inc. (GUD.TO)
finance.yahoo.com - January 16 at 2:29 PM
finance.yahoo.com logoCRH Makes GUD on Knight Secured Loan
finance.yahoo.com - November 25 at 8:00 AM
finance.yahoo.com logoKnight to Present at the TD Securities Technology & Healthcare Conference in Toronto
finance.yahoo.com - November 17 at 8:00 AM
finance.yahoo.com logoKnight Partner FOCUSed on Growth
finance.yahoo.com - November 16 at 8:00 AM
finance.yahoo.com logoKnight Supports Operation Antibe
finance.yahoo.com - November 16 at 8:00 AM
finance.yahoo.com logoKnight Reports Third Quarter Financial 2015 Results
finance.yahoo.com - November 11 at 6:00 AM
finance.yahoo.com logoThe Knight Medison Relationship Already Paying Dividends
finance.yahoo.com - November 2 at 8:00 AM
finance.yahoo.com logoKnight Profounda U.S. Partner for Impavido
finance.yahoo.com - September 28 at 8:00 AM

Social

Chart

Knight Therapeutics (GUD) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff